Evaluating Cordyceps Militaris Capsules for COPD: A 48-Week Clinical Trial Protocol

Siqi Lin published a study protocol for a double-blind, randomized, placebo-controlled trial on 2026-05-25. The protocol describes a 48-week multi-center trial involving 160 patients with mild-to-moderate COPD to evaluate the efficacy of Cordyceps militaris capsules on lung function decline. The primary outcome is the change in post-bronchodilator FEV1, with secondary measures including other lung function parameters, exacerbation frequency, and quality-of-life questionnaires.

Use Cases

• Analyzing the design of a traditional Chinese medicine clinical trial based on the described double-blind, randomized, placebo-controlled methodology.
• Studying outcome measures for COPD interventions based on the listed primary (post-bronchodilator FEV1) and secondary (CAT, mMRC, CASA-Q) endpoints.
• Benchmarking clinical trial protocols for herbal supplements in respiratory conditions based on the described 24-week treatment and 24-week follow-up structure.

Strengths

• The protocol is registered with a public clinical trial registry (ChiCTR2400086743).
• The study design is explicitly described as multi-center, randomized, double-blind, and placebo-controlled.
• The target sample size of 160 patients and a 48-week total study duration are specified.

Limitations

• The dataset is a 1.0 MB PDF protocol document; the underlying clinical trial data is not included.
• Row count and column-level documentation for the trial data are unknown.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Siqi Lin via figshare

Collection Method

Described as a clinical trial study protocol.

Freshness

Last updated 2026-05-25 06:07:16; freshness should be verified.